Mr. David J. Main

President & CEO

Mr. Main has over 25 years of experience in the pharmaceutical industry and brings a demonstrated ability to grow and finance pharmaceutical development companies. As a founder of Aquinox, Mr. Main has overseen the advancement of the company’s lead product, rosiptor (AQX-1125), from a target validation program to Phase 3 and is preparing to transition the Company to a commercially focused organization. During this time he has also been responsible for the transition of Aquinox from a private to a NASDAQ-listed public company with over US$250 million raised to date in equity capital. Mr. Main was formerly the President and CEO of INEX Pharmaceuticals Corp. and, prior to INEX, was a Vice President at QLT Inc., one of Canada’s inaugural biotech companies. Mr. Main began his career as a licensed pharmacist at the Royal Columbian Hospital in New Westminster, B.C. He holds a B.Sc. (Pharmacy) and an MBA from the University of British Columbia (UBC). Mr. Main formerly served as the Chair of LifeSciences BC (formerly BC Biotech) and BIOTECanada. He is the current Chairman of Accel-Rx, a Director of, and contributes his time to other not-for-profit organizations.


Mr. Kamran Alam

VP, Finance & Chief Financial Officer

Mr. Alam has over 15 years' experience in the pharmaceutical industry and brings a demonstrated ability to finance and identify strategic opportunities for biotechnology companies. Previously, he has held senior business roles at Sirius Genomics, the Centre for Drug Research and Development (CDRD), Angiotech Pharmaceuticals, and AnorMED. Mr. Alam started his career as a Chartered Accountant with PriceWaterhouseCoopers (PwC) as a member of their Life Sciences Practice and gained valuable experience in the financing, auditing, and tax structuring of a number of biotechnology and technology companies. Mr. Alam's diverse industry experience has provided him with an opportunity to participate in numerous and varied finance transactions, partnering deals, and mergers and acquisitions in the United States, Canada, Europe, and Asia. In addition to his CPA, CA designation, Mr. Alam possesses an MBA in International Business and Strategy from the University of Victoria as well as a B.Sc. in Cell Biology and Genetics from the University of British Columbia.


Mr. Paul Brennan

VP, Business Development

Mr. Brennan brings more than 25 years of experience in building and leading pharmaceutical and biotechnology companies in the United States, Europe, and Canada with a strong track record in partnering and licensing transactions. Previously, Mr. Brennan was Senior Vice President of Business Development at Arbutus Biopharma Corp. (formerly Tekmira Pharmaceuticals Corp.), prior to which he served as CEO of Altair Therapeutics, Inc. In past roles Mr. Brennan contributed to the sale of Aspreva Pharmaceuticals Corp. to Vifor Pharma Ltd. for $915 million and the sale of AnorMED Inc. to Genzyme Corp. for $580 million. Mr. Brennan also served in senior business development and regulatory affairs roles with AstraZeneca PLC, operating in Sweden, the United Kingdom, and Canada. 


Mr. Lloyd Mackenzie

Chief Operating Officer & Vice President, R&D Operations

Mr. Mackenzie joined Aquinox in May 2008 and was promoted to Vice President in May of 2013. Responsible for the company's research and development activities, Mr. Mackenzie has over 22 years of experience in the biopharmaceutical industry with expertise in medicinal chemistry, biochemistry, and CMC. He is the author of 15 scientific publications and is an inventor on four patents. Prior to joining Aquinox, Mr. Mackenzie was a Research Scientist for Pharmaceutical Development at QLT Inc. Prior to that, Mr. Mackenzie was a Research Scientist at Inflazyme Pharmaceuticals Inc.


Ms. Shelley McCloskey

VP, Human Resources & Administration

Ms. McCloskey has over 15 years of human resources leadership experience in the health industry. Most recently, Ms. McCloskey was Vice President, Human Resources at Stemcell Technologies Inc. (Stemcell), Canada's largest life sciences company by number of employees, with operations in North America, Europe, and Asia Pacific. Prior to joining Stemcell in 2010, Ms. McCloskey was Vice President, Human Resources at Xantrex Technology Inc., a publically traded global advanced renewable energy and power electronics company acquired by Schneider Electric for C$500M in 2008. From 2000 to 2005, Ms. McCloskey served as Vice President, Human Resources and Information Systems at Inex Pharmaceuticals Inc., helping that company grow from 40 to 225 employees.


Dr. Barbara Troupin

Chief Medical Officer & VP, Clinical Development & Regulatory Affairs

Dr. Troupin joined Aquinox in October of 2016 with more than 18 years’ experience leading clinical and medical affairs functions. Dr. Troupin has led clinical development and strategy at multiple leading clinical research institutions and within the therapeutic drug development sector. Dr. Troupin most recently served as Senior Vice President and Chief Medical Officer at Apricus Bioscience, Inc., where she led the development and execution of clinical strategy for three drug development programs ranging from proof-of-concept to NDA filing, including Vitaros for the treatment of erectile dysfunction. Prior to Apricus, Dr. Troupin held the role of Vice President in Medical Affairs at VIVUS, Inc., where she led risk evaluation and mitigation strategy for Qsymia to treat weight loss, a product whose development and approval she had been instrumental in, while also responsible for building relationships with key opinion leaders (KOLs) and other key stakeholders. Dr. Troupin received her Doctorate in Medicine in 1995 from the University of Pennsylvania School of Medicine, where she also completed her Master's in Business Administration with an emphasis in health care management from the Wharton School of Business.